{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:47:27Z","timestamp":1748220447681},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Foundation of the President of the Russian Federation for Young Doctors of Sciences","award":["MD 901.2013.7"],"award-info":[{"award-number":["MD 901.2013.7"]}]},{"DOI":"10.13039\/501100002261","name":"Russian Foundation for Basic Research","doi-asserted-by":"publisher","award":["13-04-01381"],"award-info":[{"award-number":["13-04-01381"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.prp.2015.03.005","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T22:53:01Z","timestamp":1428274381000},"page":"521-527","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma"],"prefix":"10.1016","volume":"211","author":[{"given":"M.B.","family":"Aksenenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.K.","family":"Kirichenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.G.","family":"Ruksha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2015.03.005_bib0245","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1158\/1055-9965.EPI-14-0295","article-title":"Risk prediction models for melanoma: a systematic review","volume":"23","author":"Usher-Smith","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.prp.2015.03.005_bib0250","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.7314\/APJCP.2014.15.5.2201","article-title":"Melanoma incidence mortality rates and clinico-pathological types in the Siberian Area of the Russian Federation","volume":"15","author":"Gyrylova","year":"2014","journal-title":"Asian. Pac. J. Cancer Prev."},{"key":"10.1016\/j.prp.2015.03.005_bib0255","first-page":"449","article-title":"Prognostic factors for melanoma progression and metastasis: from hematoxylin\u2013eosin to genetics","volume":"53","author":"Fernandez-Flores","year":"2012","journal-title":"Rom. J. Morphol. Embryol."},{"key":"10.1016\/j.prp.2015.03.005_bib0260","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1158\/0008-5472.CAN-04-3625","article-title":"Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations","volume":"65","author":"Pohl","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2015.03.005_bib0265","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","article-title":"BRAF: implications for carcinogenesis and molecular therapy","volume":"10","author":"Cantwell-Dorris","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2015.03.005_bib0270","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1200\/JCO.2012.47.0104","article-title":"Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication","volume":"31","author":"Mahoney","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2015.03.005_bib0275","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2015.03.005_bib0280","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/DAD.0b013e3181584950","article-title":"Distribution of BRAF T1799A (V600E) mutations across various types of benign nevi: implications for melanocytic tumorigenesis","volume":"29","author":"Wu","year":"2007","journal-title":"Am. J. Dermatopathol."},{"key":"10.1016\/j.prp.2015.03.005_bib0285","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/jnci\/djp309","article-title":"Polyclonality of BRAF mutations in acquired melanocytic nevi","volume":"101","author":"Lin","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.prp.2015.03.005_bib0290","doi-asserted-by":"crossref","first-page":"286","DOI":"10.4161\/cc.11.2.18707","article-title":"The BRAF (V600E) causes wide spread alterations in gene methylation in the genome of melanoma cells","volume":"11","author":"Hou","year":"2012","journal-title":"Cell Cycle"},{"key":"10.1016\/j.prp.2015.03.005_bib0295","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.prp.2015.03.005_bib0300","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.1158\/1078-0432.CCR-12-1632","article-title":"Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma","volume":"18","author":"Khalili","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2015.03.005_bib0305","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1158\/2326-6066.CIR-13-0215","article-title":"Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade","volume":"2","author":"Cooper","year":"2014","journal-title":"Cancer Immunol."},{"key":"10.1016\/j.prp.2015.03.005_bib0310","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1158\/1078-0432.CCR-13-0898","article-title":"Molecular pathways: BRAF induces bioenergetic adaptation by attenuating oxidative phosphorylation","volume":"20","author":"Haq","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2015.03.005_bib0315","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"JCO"},{"key":"10.1016\/j.prp.2015.03.005_bib0320","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","article-title":"BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor and the degree of solar elastosis at the primary tumor site","volume":"24","author":"Bauer","year":"2011","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.prp.2015.03.005_bib0325","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1371\/journal.pmed.0050120","article-title":"Improving melanoma classification by integrating genetic and morphologic features","volume":"5","author":"Viros","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.prp.2015.03.005_bib0330","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.jid.5700632","article-title":"Distinct clinical and pathological features are associated with the Braf (T1799a (V600e)) mutation in primary melanoma","volume":"127","author":"Liu","year":"2007","journal-title":"Investig. Dermatol."},{"key":"10.1016\/j.prp.2015.03.005_bib0335","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1177\/0194599813481942","article-title":"Clinical significance of BRAF mutation in thyroid papillary cancer","volume":"148","author":"Fernandez","year":"2013","journal-title":"Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.prp.2015.03.005_bib0340","first-page":"4619","article-title":"Clinical significance of BRAF gene mutations in patients with non-small cell lung cancer","volume":"31","author":"Kobayashi","year":"2011","journal-title":"Anticancer Res."},{"key":"10.1016\/j.prp.2015.03.005_bib0345","doi-asserted-by":"crossref","first-page":"6063","DOI":"10.1158\/0008-5472.CAN-05-0404","article-title":"Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers","volume":"65","author":"Samowitz","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2015.03.005_bib0350","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1093\/annonc\/mdq258","article-title":"The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients","volume":"21","author":"Fari\u00f1a-Sarasqueta","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2015.03.005_bib0355","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-11-2197","article-title":"Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma","volume":"18","author":"Luke","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2015.03.005_bib0360","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1158\/0008-5472.CAN-11-1875","article-title":"Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation","volume":"72","author":"Su","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2015.03.005_bib0365","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1535-7163.MCT-12-0530","article-title":"Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine","volume":"11","author":"Wilmott","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2015.03.005_bib0370","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2015.03.005_bib0375","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/CMR.0000000000000090","article-title":"Sensitive allele-specific real-time PCR test for mutations in BRAF codon V600 in skin melanoma","volume":"24","author":"Piisareva","year":"2014","journal-title":"Melanoma Res."},{"key":"10.1016\/j.prp.2015.03.005_bib0380","first-page":"716","article-title":"Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies","volume":"109","author":"McCarty","year":"1985","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.prp.2015.03.005_bib0385","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/jnci\/81.24.1893","article-title":"A model for predicting survival in stage 1 melanoma based upon tumor progression","volume":"81","author":"Clark","year":"1981","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.prp.2015.03.005_bib0390","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1309\/G6EK-Y6EH-0LGY-6D6P","article-title":"Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma: a study of interobserver agreement","volume":"115","author":"Busam","year":"2001","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.prp.2015.03.005_bib0395","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1309\/AJCPTXMEFOVYWDA6","article-title":"Presence of tumor-infiltrating lymphocytes and a dominant nodule within primary melanoma are prognostic factors for relapse-free survival of patients with thick (T4) primary melanoma: pathologic analysis of the E1690 and E1694 intergroup trials","volume":"133","author":"Rao","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.prp.2015.03.005_bib0400","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2015.03.005_bib0405","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/jid.2009.182","article-title":"The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population","volume":"130","author":"Hacker","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.prp.2015.03.005_bib0410","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1186\/1477-3163-3-6","article-title":"Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis","volume":"3","author":"Houben","year":"2004","journal-title":"J. Carcinog."},{"key":"10.1016\/j.prp.2015.03.005_bib0415","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1186\/1479-5876-2-46","article-title":"Clinical significance of BRAF mutations in metastatic melanoma","volume":"2","author":"Chang","year":"2004","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.prp.2015.03.005_bib0420","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1371\/journal.pone.0000236","article-title":"B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis","volume":"2","author":"Ugurel","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.prp.2015.03.005_bib0425","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","article-title":"Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort","volume":"48","author":"Si","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2015.03.005_bib0430","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","article-title":"Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma","volume":"29","author":"Long","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.prp.2015.03.005_bib0435","doi-asserted-by":"crossref","first-page":"e69639","DOI":"10.1371\/journal.pone.0069639","article-title":"NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi","volume":"8","author":"Tschand","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.prp.2015.03.005_bib0440","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1158\/1078-0432.CCR-1169-3","article-title":"Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas","volume":"10","author":"Shinozaki","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.prp.2015.03.005_bib0445","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1093\/jnci\/djg123","article-title":"Determinants of BRAF mutations in primary melanomas","volume":"95","author":"Maldonado","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.prp.2015.03.005_bib0450","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/jid.2009.332","article-title":"Melanoma molecular subtypes: unifying and paradoxical results","volume":"130","author":"Thomas","year":"2010","journal-title":"J. Investig. Dermatol."},{"key":"10.1016\/j.prp.2015.03.005_bib0455","first-page":"139","article-title":"The oncogenic BRAF V599e mutation occurs more frequently in melanomas at sun-protected body sites","volume":"29","author":"Deichmann","year":"2006","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.prp.2015.03.005_bib0460","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1046\/j.1365-2559.2002.01444.x","article-title":"Ki67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma","volume":"41","author":"Ben-Izhak","year":"2002","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2015.03.005_bib0465","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/thy.2011.0401","article-title":"The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpression","volume":"22","author":"Grabellus","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.prp.2015.03.005_bib0470","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1158\/0008-5472.CAN-06-0739","article-title":"Conditional activation of RET\/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling","volume":"66","author":"Mesa","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.prp.2015.03.005_bib0475","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1677\/ERC-07-0212","article-title":"BRAF (V600E) mutation and the biology of papillary thyroid cancer","volume":"15","author":"Frasca","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.prp.2015.03.005_bib0480","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1634\/theoncologist.2012-0333","article-title":"Analysis of dermatologic events in vemurafenib-treated patients with melanoma","volume":"18","author":"Lacouture","year":"2013","journal-title":"Oncologist"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033815000552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033815000552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,22]],"date-time":"2019-08-22T20:12:54Z","timestamp":1566504774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033815000552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0344033815000552"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2015.03.005","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Russian study of morphological prognostic factors characterization in BRAF-mutant cutaneous melanoma","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2015.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}]}}